Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Lexaria Announces Positive Feedback from Pre-IND Meeting
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Kelowna, British Columbia – TheNewswire - June 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC (“BevNology”).
Kelowna, British Columbia - TheNewswire – October 5, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.